IN THE SPOTLIGHT

Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC

Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC

Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD

Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD

Tepmetko Associated With Frequent Side Effects for Some With NSCLC

Tepmetko Associated With Frequent Side Effects for Some With NSCLC

Long-term complete remission with immunotherapy in advanced RET fusion-positive NSCLC with brain metastases: a case report and literature review

Long-term complete remission with immunotherapy in advanced RET fusion-positive NSCLC with brain metastases: a case report and literature review

Recognizing and Testing for ROS1 in NSCLC

Recognizing and Testing for ROS1 in NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

袁双虎教授:从 WCLC 到 CSCO,聚焦 HER2 变异 NSCLC 治疗新进展_腾讯新闻

袁双虎教授:从 WCLC 到 CSCO,聚焦 HER2 变异 NSCLC 治疗新进展_腾讯新闻

刘安文教授:德曲妥珠单抗破局 HER2 过表达 NSCLC 治疗困境,检测优化是前提 | WCLC 2025_腾讯新闻

刘安文教授:德曲妥珠单抗破局 HER2 过表达 NSCLC 治疗困境,检测优化是前提 | WCLC 2025_腾讯新闻

Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials

Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials